Welcome to our dedicated page for Psychemedics news (Ticker: PMD), a resource for investors and traders seeking the latest updates and insights on Psychemedics stock.
Psychemedics Corporation (PMD) is a global provider of hair testing for drugs of abuse, and its news flow reflects developments in drug detection, analytics, and corporate strategy. On this page, readers can follow announcements about new testing services, analytical tools, and multi-year insights derived from the company’s large database of hair test results.
Recent Psychemedics news has highlighted the launch of specialized offerings such as ketamine hair testing, which is designed for use in workplace safety programs, educational institutions, rehabilitation centers, and law enforcement agencies. The company has also introduced Enhanced Quartile Reporting, an analytics feature that places positive results into population-based quartiles to give employers deeper context about the severity of drug use and behavioral risk patterns.
Another recurring theme in Psychemedics’ news is the publication of Insights Reports and Workforce Insights Reports. These reports analyze hundreds of thousands of hair samples over multiple years to identify trends in substances such as marijuana, cocaine, methamphetamine, fentanyl, synthetic opioids, nicotine, and amphetamines. Sector-specific findings for industries like transportation, manufacturing, healthcare, and education are frequently discussed.
Corporate updates also appear in the news stream, including the relocation of the company’s headquarters to Dallas, Texas, and plans to undertake a reverse and forward stock split in connection with a proposed delisting and deregistration of its common stock. Investors, employers, educators, and policymakers can use this news page to follow how Psychemedics’ services, data, and corporate structure evolve over time and to monitor developments that may affect workplace and community drug testing practices.
Psychemedics (NASDAQ: PMD), a leading entity in hair testing for drugs, has launched its inaugural Insights Report. This comprehensive report analyzes drug trends in the workplace, derived from hundreds of thousands of hair samples collected in 2023. The report reveals an overall positive drug test rate of 9.5%, with a 23% increase in positive rates over the last five years. Marijuana, cocaine, and opiates are the most detected substances, while fentanyl shows a troubling rise. The report underscores the effectiveness of hair testing for employment drug screening and aims to help employers and policymakers address workplace drug use. More details can be accessed at the provided link.
Psychemedics (NASDAQ: PMD), a leading provider of hair testing for drugs of abuse, announced its Q1 2024 financial results on May 14, 2024. For the quarter ended March 31, 2024, the company reported a revenue of $5.4 million, down 9% from $5.9 million in the same quarter of the previous year. The net loss for Q1 2024 was $0.7 million, or $0.12 per share, compared to a net loss of $0.4 million, or $0.07 per share, in Q1 2023. Despite the decline, CEO Brian Hullinger expressed optimism about future growth and revenue stabilization, highlighting the company's ongoing efforts to explore new markets and applications for its hair testing solutions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.